PFE — Clinical Trial Completion for Disitamab Vedotin
Jul 28, 2029, 4:00:00 AM UTC
Summary
The clinical trial evaluating disitamab vedotin in combination with tucatinib is expected to complete on July 28, 2029, focusing on HER2-expressing cancers. This Phase 2 trial, sponsored by Seagen Inc., a subsidiary of Pfizer, aims to assess the safety and efficacy of the combination therapy in patients with locally advanced or metastatic breast and gastric cancers. The trial includes a dose escalation and optimization phase, followed by an expansion phase with multiple cohorts.
Company
PFIZER INC (PFE)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.pfizer.comSimilar Events
Phase 2 Clinical Trial Completion for Disitamab Vedotin in HER2+ Solid Tumors
A Phase 2 clinical trial evaluating disitamab vedotin, an antibody-drug conjugate (ADC), in patients with advanced or metastatic HER2-expressing solid tumors is expected to complete on May 31, 2028. The study, sponsored by Seagen Inc., a Pfizer subsidiary, targets cancers including head and neck, non-small cell lung, endometrial, and ovarian cancers. The trial aims to assess the efficacy and safety of disitamab vedotin, with 119 participants enrolled.
trial completionPhase 3 Trial Completion: Disitamab Vedotin + Pembrolizumab in Urothelial Cancer
A Phase 3 clinical trial evaluating disitamab vedotin in combination with pembrolizumab versus platinum-based chemotherapy in previously untreated HER2-expressing urothelial cancer is expected to complete on April 30, 2029. The study, sponsored by Seagen Inc. with Merck's pembrolizumab, is enrolling 400 participants and aims to assess efficacy and safety in metastatic or locally advanced disease. Disitamab vedotin is an antibody-drug conjugate, while pembrolizumab is an anti-PD-1 immunotherapy.
trial completionExpected Trial Completion for Tisotumab Vedotin Study
A Phase 2 clinical trial evaluating tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in patients with selected solid tumors is expected to complete on August 14, 2026. The study, sponsored by Seagen (a Pfizer subsidiary) and involving Genmab (GMAB), is assessing efficacy, safety, and tolerability in tumor types including colorectal cancer, squamous non-small cell lung cancer, exocrine pancreatic adenocarcinoma, and head and neck squamous cell carcinoma. The trial has enrolled 352 participants and is not currently recruiting.
trial completionTisotumab Vedotin Cervical Cancer Trial Completion
The Phase 1/2 clinical trial evaluating Tisotumab Vedotin, an antibody-drug conjugate, as monotherapy and in combination with other agents for cervical cancer is expected to complete on March 31, 2026. The study, sponsored by Seagen (a Pfizer subsidiary) and involving Genmab (GMAB), assesses safety and efficacy in patients with recurrent or advanced cervical cancer across multiple treatment arms. Tisotumab Vedotin is a targeted therapy designed to deliver cytotoxic agents directly to cancer cells, and is categorized as an oncology biologic.
trial completion